NCT06946589

Cardiac Changes After Effective Dose Carbetocin for Elective Caesarian Section

• Status: Not Yet Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Jordan Leitch · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this project is to examine the cardiac symptoms and physiologic changes after administration of a reduced dose of carbetocin in participants undergoing elective cesarian section. * Does reduced dose carbetocin (50mcg) have fewer cardiac side effects than usual dose carbetocin (100mcg) when comparing patient reported symptoms, ECG changes and troponin increases? * Is there a relationship between patient reported cardiac symptoms after carbetocin administration and subjective measures of cardiac ischemia (ECG changes and troponin increases? Researchers will compare 50mcg of carbetocin to the control group of 100mcg of carbetocin in patients undergoing elective cesarian section. Participants will: * Be given 50mcg or 100mcg of carbetocin during cesarian section * Asked to report cardiac symptoms * Be assessed for ECG changes and blood loss using standard of practice monitoring * Have a troponin I blood test completed after delivery

Conditions

• Cardiac Ischemia
• Cesarian Section

Interventions

Type	Name	Description
DRUG	Carbetocin	A uterotonic agent used for the prevention of postpartum hemorrhage in Cesarian section

Timeline

• Start date: 2025-08-01
• Primary completion: 2026-08-01
• Completion: 2027-09-01
• First posted: 2025-04-27
• Last updated: 2025-04-27

Locations

1 site across 1 country: Canada